INVO Fertility Reports 17% Revenue Growth and Net Income Turnaround in Q2 2026

INVO Fertility, Inc. reported its financial results for the second quarter of 2026, revealing a total revenue of approximately $2.18 million, a notable increase of 17% from $1.86 million in the same period last year. The growth was primarily driven by the addition of the Family Beginnings clinic, which contributed significantly to the company's clinic revenue, which rose to $2.17 million from $1.83 million year-over-year. However, product revenue saw a decline, dropping to $7,700 from $31,560 in the prior year, reflecting a shift in focus towards clinic operations.

The company's operating expenses for the quarter decreased to $3.47 million from $4.85 million in the previous year, largely due to the absence of a significant impairment loss that had impacted the prior year's results. The loss from operations improved to $1.29 million compared to a loss of $2.99 million in the same quarter of 2025. Notably, INVO Fertility recorded a net income of $888,740 for the quarter, a significant turnaround from a net loss of $3.62 million in the prior year, attributed to a gain on the remeasurement of a note receivable and a reduction in interest expenses.

Strategically, INVO Fertility has been active in expanding its footprint in the fertility market. The company completed the acquisition of Family Beginnings in February 2026 for a total purchase price of $760,000, which included cash and preferred stock. Additionally, in June 2026, INVO acquired 100% of HRCFG, further solidifying its presence in the fertility clinic sector. As of June 30, 2026, the company operated four fertility clinics in the United States, with plans for further expansion.

Operationally, INVO Fertility reported a total of 2,506,969 shares of common stock outstanding as of August 14, 2026. The company has also been focusing on improving its liquidity, with cash reserves increasing to approximately $3.73 million from $0.55 million a year earlier. The company’s accumulated deficit stood at approximately $96 million, reflecting ongoing challenges in achieving profitability. Looking ahead, INVO Fertility aims to continue its growth trajectory through organic revenue generation and additional acquisitions, while also addressing its liquidity needs through potential capital raises.

The company remains cautious about its future, acknowledging the need for additional funding to support its operations and growth strategy. Management has indicated that while they are optimistic about the expansion of their clinic operations and the INVOcell device, they will need to secure further financing to ensure the sustainability of their business model.